Sra-333
Metastatic Disease
Wake Forest University Health SciencesPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Metastatic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Regorafenib Shanghai Runshi Pharmaceutical Technology Co., Ltd | Phase 2 | BB |
Temsirolimus Sandy Srinivas | Phase 3 | B |
Sorafenib University Health Network, Toronto | Phase 2 | B |
4-1BBL Hadassah Medical Organization | Phase 2/3 | CCC |
Melanoma Vaccine Modified To Express Hla A2/4-1Bb Ligand Hadassah Medical Organization | Phase 2/3 | CCC |
View all 18 →
Same molecule, other indications
Sra-333 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →